- Home
- LU vs SRPT Comparison
LU vs SRPT Comparison
Compare LU & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | SRPT |
|---|---|---|
| Founded | 2005 | 1980 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LU | SRPT |
|---|---|---|
| Price | $3.12 | $17.84 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 28 |
| Target Price | N/A | ★ $25.76 |
| AVG Volume (30 Days) | 1.5M | ★ 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.67 |
| Revenue Next Year | $22.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $10.42 |
| 52 Week High | $4.57 | $110.00 |
Technical Indicators
Market Signals| Indicator | LU | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 65.89 | 37.96 |
| Support Level | $2.66 | $17.24 |
| Resistance Level | $2.73 | $18.19 |
| Average True Range (ATR) | 0.13 | 1.08 |
| MACD | 0.03 | -0.25 |
| Stochastic Oscillator | 86.90 | 18.59 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.